CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

CSL strikes $1.55B lixudebart deal with Alentis for rare kidney and liver diseases

lixudebartPositive
AI Analysis

Summary

CSL announced a $1.55 billion acquisition deal with Alentis to obtain lixudebart, a drug candidate for rare kidney and liver diseases.

Importance:7/10
Sentiment:
0.60
M&Aacquisitionrare diseaseskidney diseaseliver disease
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on October 5, 2026 6:17 AM

Read Original